EGFR amplification is common in glioblastoma and represents a therapeutic challenge, conferring resistance to targeted treatment. A new study reveals that the same locus hides the HELDR lncRNA, which epigenetically activates KAT7 to drive growth independently of EGFR. Targeting HELDR or KAT7 may improve anti-EGFR therapies in glioblastoma.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Westphal, M., Maire, C. L. & Lamszus, K. CNS Drugs 31, 723–735 (2017).
Yu, X. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-026-01924-w (2026).
Noorani, I. et al. Cancer Discov. 15, 2078–2095 (2025).
Purshouse, K. et al. eLife 11, e80207 (2022).
deCarvalho, A. C. et al. Nat. Genet. 50, 708–717 (2018).
Lassman, A. B. et al. Neuro Oncol. 25, 339–350 (2023).
Rinaldi, C. & Wood, M. J. A. Nat. Rev. Neurol. 14, 9–21 (2018).
Huarte, M. Nat. Med. 21, 1253–1261 (2015).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhawan, A., Lathia, J.D. lncRNA in EGFR‑driven glioblastoma. Nat Cell Biol (2026). https://doi.org/10.1038/s41556-026-01947-3
Published:
Version of record:
DOI: https://doi.org/10.1038/s41556-026-01947-3
